Yarrow Bioscience, Inc. (YARW)

NASDAQ: YARW · USD

$18.8

-1.28 (-6.4%)· Recorded snapshot

Market cap	175.3M
Net income (ttm)	-284M
EPS (ttm)	-$66.8
Shares out	9.3M
Volume	252,509
Beta	2.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -284M
EPS (ttm): -$66.8
Market cap: 175.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All YARW indicators

Market & fundamental data

Available fields

162

Groups with data

Currency

USD

Showing 162 of 162 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001566044
Company name	Yarrow Bioscience, Inc.
Country	United States
Country code	US
CUSIP number	92941V407
Earnings date	2026-11-10
Earnings time	amc
Employees	7
Enterprise value	$75.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-07-30
Fiscal year end	December
Founded	2021
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US92941V4077
Last 10-K release date	2026-02-27
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2026-07-27
Last stock split type	Reverse
Market cap	$175.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	No
Price	$18.84
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	YARW
U.S. state	New York
Website	https://www.yarrowbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-354.66%
FCF / EV yield	-19.42%
FCF yield	-9.05%
P/B ratio	6.49x
P/OCF ratio	334.29x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-40.6M
ROCE	-13.78%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	8
Net income growth quarters	5
Net income growth years	1
Revenue growth quarters	1
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-4M
EPS	$-66.82
FCF per share	$-1.82
Financing cash flow	$399.4M
Free cash flow	$-16.9M
Net cash flow	$400M
Net income	$-284M
Operating income	$-4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-16.70
Debt / equity	0
Long-term assets	$77.1M
Long-term liabilities	$66.4M
Net cash (debt)	$100M
Net cash / market cap	53.41%
Net debt / equity	-3.46
Piotroski F-Score	2
Shareholders' equity	$28.9M
Tangible book value	$-71M
Tangible book value per share	$-16.70
Total assets	$100.4M
Total cash	$100M
Total debt	$0
Total liabilities	$71.5M
WACC	15.69%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$23.3M
Current liabilities	$5.2M
Current ratio	1.4
Net working capital	$-71.5M
Quick ratio	1.4
Working capital	$28.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend growth years	0
Dividend payment date	2026-07-23
Dividend payment years	1
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$20.12

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$31.39
1D price change	-6.36%
1M price change	-23.16%
1M total return	-23.16%
1W price change	-2.89%
1W total return	-2.89%
1Y price change	8.73%
1Y return CAGR	92.8%
1Y total return	92.71%
20-day SMA	$19.89
200-day SMA	$30.85
3M price change	-31.29%
3M total return	-31.29%
3Y price change	-82.52%
3Y return CAGR	-32.32%
3Y total return	-69.01%
50-day SMA	$26.36
50-day SMA vs 200-day SMA	50under200
52-week high	$46.95
52-week high date	2026-07-23
52-week low	$16.04
52-week low date	2025-11-05
5Y price change	-98.27%
5Y return CAGR	-50.19%
5Y total return	-96.93%
6M price change	-38.53%
6M total return	8.96%
All-time high	$14,579.99
All-time high date	2020-03-10
All-time low	$14.03
All-time low date	2025-09-09
Average true range (ATR)	$1.76
Average volume	124.2K
Beta (1Y)	1.27
Beta (2Y)	1.6
Beta (5Y)	2.08
Change from 52-week high	-59.87%
Change from 52-week low	17.46%
Change from all-time high	-99.87%
Change from all-time low	39.93%
Change from open	-4.9%
Day's gap	-1.54%
Dollar volume	$4.8M
High price	$19.81
Low price	$18.76
Monthly RSI	29.2
Open price	$19.81
Position in 52-week range	7.62%
Previous close	$20.12
Price vs 150-day SMA	-37.48%
Price vs 20-day SMA	-1.35%
Price vs 200-day SMA	-36.39%
Price vs 50-day SMA	-25.55%
Relative volume	2.03
RSI	39.28
Sharpe ratio	1.15
Sharpe ratio (3Y)	0.06
Sharpe ratio (5Y)	-0.14
Sortino ratio	2.57
Sortino ratio (3Y)	0.14
Sortino ratio (5Y)	-0.15
Volume	252.5K
Weekly RSI	37.58
YTD price change	-32.34%
YTD total return	19.92%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8.6M
Float percentage	92.75%
Shares change (QoQ)	-28.29%
Shares held by insiders	0.9%
Shares held by institutions	32.98%
Shares outstanding	9.3M
Short % of float	1.53%
Short % of shares	1.42%
Short ratio	1 days

Deeper analysis on YARW

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this YARW report

Is a complete YARW research report available?

No complete published report is available for Yarrow Bioscience, Inc. (YARW) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Yarrow Bioscience, Inc. (YARW)

Price

Financial snapshot

Fair-value bridge

Latest news · YARW

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All YARW indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on YARW

Frequently asked questions